- Home
- ZURA vs AVIR Comparison
ZURA vs AVIR Comparison
Compare ZURA & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | AVIR |
|---|---|---|
| Founded | 2022 | 2012 |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.8M | 450.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZURA | AVIR |
|---|---|---|
| Price | $5.93 | $5.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $11.78 | $8.00 |
| AVG Volume (30 Days) | 475.6K | ★ 578.2K |
| Earning Date | 03-19-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $2.46 |
| 52 Week High | $7.25 | $6.45 |
Technical Indicators
Market Signals| Indicator | ZURA | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 44.56 |
| Support Level | $5.62 | $3.33 |
| Resistance Level | $6.99 | $6.45 |
| Average True Range (ATR) | 0.49 | 0.29 |
| MACD | -0.09 | -0.15 |
| Stochastic Oscillator | 34.16 | 5.36 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.